Curti, B., Daniels, G. A., McDermott, D. F., Clark, J. I., Kaufman, H. L., Logan, T. F., . . . Dutcher, J. P. (2017). Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: Data from the PROCLAIM(SM) registry. J Immunother Cancer.
Chicago Style CitationCurti, Brendan, et al. "Improved Survival and Tumor Control With Interleukin-2 Is associated With the Development of Immune-related Adverse Events: Data From the PROCLAIM(SM) Registry." J Immunother Cancer 2017.
Cita MLACurti, Brendan, et al. "Improved Survival and Tumor Control With Interleukin-2 Is associated With the Development of Immune-related Adverse Events: Data From the PROCLAIM(SM) Registry." J Immunother Cancer 2017.